| Similar Articles |
|---|
 |
The Motley Fool
July 20, 2004
Brian Gorman |
Bayer Reshuffles Business Bayer, one of Germany's most venerable industrial names, is revamping its house. Seemingly in one fell swoop, the company is spinning off its Lanxess chemicals and polymers unit and buying Roche's over-the-counter-drugs business.   |
The Motley Fool
March 3, 2005
Brian Gorman |
Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors. |
The Motley Fool
October 16, 2006
Brian Lawler |
Bayer's Big Drug Boo-Boo The company's forgetfulness could end up hurting its reputation even worse than its revenues. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
Pharmaceutical Executive
November 1, 2006
Patrick Clinton |
Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business. |
The Motley Fool
September 5, 2006
Brian Gorman |
Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list. |
The Motley Fool
November 30, 2006
Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note. |
Chemistry World
July 5, 2012 |
Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms. |
The Motley Fool
August 29, 2006
S.J. Caplan |
Bayer's Crop Headache The company's second-quarter earnings are up while crops drag. Investors, take note. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
October 13, 2011
Sean Williams |
How to Turn Onyx Into Gold A settlement with Bayer turns Onyx into an instant buyout candidate. |
Chemistry World
September 23, 2014
Andy Extance |
Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months. |
The Motley Fool
July 29, 2010
Brian Orelli |
Forget Respect -- Dendreon Needs Sales! Dendreon's Provenge was approved months ago, but the data from the clinical trial supporting the FDA's decision was finally published in the New England Journal of Medicine this week. |
The Motley Fool
December 5, 2006
Brian Lawler |
Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder. |
Chemistry World
June 22, 2007
Ned Stafford |
Big Pharma Not Interested in 'Male Pill' German drug giant Bayer has officially stopped research and development of a hormonal male contraceptive, yet another sign that the pharma industry has lost interest in developing the so-called 'male pill.' |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 30, 2010
Brian Orelli |
2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
November 29, 2010
Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
February 24, 2009
Brian Orelli |
Back to the Red, but Not for Long After a few quarters in the black, Onyx Pharmaceuticals slips back into the red, reporting a loss of $30 million for the fourth quarter. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
March 27, 2006
Rich Smith |
Bayer Prescribes Itself a Buyout Bayer's bid for Schering trumped an earlier $17.5 billion offer from yet another German powerhouse, Merck KGaA. Why would Bayer pay so much for Schering? Investors, take note. |
Chemistry World
May 9, 2014
Andy Extance |
Bayer wins race to buy Merck & Co consumer care Germany's Bayer has won a bidding contest for US giant Merck & Co's consumer care business unit, seemingly thanks to a heart drug collaboration sweetener. |
Chemistry World
November 16, 2012
Andrew Turley |
What lies within Bayer is looking to 'modestly' increase its R&D budget next year -- it was 3 billion euros( 2.4 billion pounds) for 2012 -- and place new emphasis on transferring ideas between research areas within the company. |
The Motley Fool
September 25, 2007
Brian Orelli |
Onyx Moves Ahead Bayer and Onyx score a positive recommendation from an EU committee, moving one step closer to being able to market their cancer-fighting drug Nexavar in Europe. |
The Motley Fool
August 27, 2007
Brian Orelli |
Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up. |
The Motley Fool
June 25, 2008
Brian Orelli |
An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets. |
The Motley Fool
September 23, 2009
Brian Orelli |
Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
Chemistry World
September 25, 2015
Rebecca Trager |
Bayer CropScience pays $5.6m to settle 2008 accident charges Under the agreement, the company will enhance safeguards at its US chemical facilities. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
BusinessWeek
April 15, 2010
Naomi Kresge |
As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives |
The Motley Fool
February 22, 2006
Rich Smith |
1001 Teutonic Nights, Part 2 Investors, get to know Germany: BASF... Bayer... SGL Carbon... Pfeiffer Vacuum... |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
The Motley Fool
June 8, 2010
Brian Orelli |
Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
Chemistry World
October 31, 2012
Andrew Turley |
Bayer spends $1.2bn on supplement maker German healthcare giant Bayer has struck a deal to buy Schiff Nutrition, a US company specializing in vitamins and nutritional supplements, for $1.2 billion. |
The Motley Fool
April 2, 2004
Brian Gorman |
Bayer's Food Fight Bayer's recent U.K. troubles reflect Europe's continued distaste for genetically modified foods. |
The Motley Fool
May 18, 2009
Brian Orelli |
Onyx Cries, "Et Tu, Brute?" The company is suing for the rights to a drug that marketing partner Bayer is developing. |
The Motley Fool
June 11, 2010
Brian Orelli |
25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed. |
The Motley Fool
April 6, 2011
Brian Orelli |
$1 Billion in Drug Sales Bleeds Out Don't feel too bad for Bayer and J&J though. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
BusinessWeek
June 23, 2011
Naomi Kresge |
Bayer Aspirin Is Feeling Plenty Healthy While J&J's Tylenol recovers from a recall, sales of century-old Bayer are soaring. |
The Motley Fool
May 8, 2009
Brian Orelli |
Growth in All the Wrong Places The potential of Onyx's tumor drug Nexavar will always be a major component in the company's value, but investors should watch the growth in current indications -- and where it's coming from -- in case the additional indications don't pan out. |
